Drexel Morgan & Co.
Three Radnor Corporate Center, Suite 450, Radnor, PA, 19087, United States
Overview
Drexel Morgan & Co is an investment adviser and bank holding company that offers personalized investment management services. The company provides its services for high net worth individuals, families, trusts, retirement plans, charitable organizations, endowments, corporations, and pooled investment vehicles. It manages separate client-focused portfolios. It invests in public equity and fixed income markets in the United States. Drexel Morgan & Co is based in Radnor, Pennsylvania.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Financial Services
Investment portfolio
- Abionic
Participated · Series B · Oct 2014
Abionic develops and commercializes the abioSCOPE, a nanotechnology rapid diagnostic platform for clinical laboratories and point-of-care use. The system uses a single drop of blood and supports tests for allergies, iron deficiency, and a pancreatic stone protein (PSP) sepsis test that provides an indication within five minutes. The company has obtained FDA registration for its first rapid allergy tests in the United States. Proceeds from the financing will be used to expand its point-of-care IVD test portfolio for critical care and emergency medicine. Abionic is launching a multinational sepsis impact study beginning April 2018 to evaluate the PSP test in over 300 patients across 14 ICU sites in Switzerland, Italy, France, and the UK. Founded in 2010 and based at the Biopôle in Lausanne, Abionic is positioning its rapid tests for earlier sepsis detection and emergency-department risk stratification. Abionic is a medical device startup based in Lausanne, Switzerland, founded in 2010 as a spinoff from EPFL. It develops abioSCOPE, a point-of-care diagnostic tool that provides patients with personal allergy profiles. The system mixes a patient’s blood sample with a proprietary reagent and places it into a test capsule containing multiple biosensors capable of detecting a specific range of allergies. abioSCOPE tests are designed to complement skin tests by offering specific, quantitative and personalized serological in vitro allergy analysis at the point of care. The company closed a CHF3.8M Series B financing round to support regulatory and commercialization efforts. Abionic intends to use the funds to obtain FDA 510(k) certification and to begin commercialization in 2015, and added Martine Reindle and Urs Amstutz to its board. Abionic SA is a Swiss MedTech company focused on allergy diagnostics. It is developing a portable biomedical device intended to improve or potentially revolutionize the diagnosis of allergies. The article describes the device as portable and biomedical but provides no technical or commercialization details. Abionic recently closed a CHF 2 million first financing round. That financing signals external venture backing from multiple Swiss investors. No operating metrics, revenues, users, or founding year are provided in the article.
Team
No current team members are available.